Key result
Doxorubicin impairs cardiac function and disrupts mitochondrial integrity in rat cardiotoxicity models.
Why the study?
The clinical use of the chemotherapeutic agent doxorubicin is limited by cardiotoxic effects, prompting this investigation into the relationship between doxorubicin-induced cardiotoxicity and mitochondrial dysfunction.
Does doxorubicin treatment cause cardiac dysfunction and mitochondrial impairment in a rat model?
Does doxorubicin treatment cause cardiac dysfunction and mitochondrial impairment in a rat model?
Preclinical evidence in a rat model indicates that mitochondrial damage and oxidative stress are central mechanisms in doxorubicin-induced cardiotoxicity.
Answers are grounded in this paper and cite their sources.
Highlights need for cardioprotection with doxorubicin; extends rat-model insights but leaves clinical translation open.
Doxorubicin (DOX) is an effective chemotherapeutic agent widely used to treat various cancers. However, its clinical use is significantly dependent cardiotoxic effects, which lead to cardiac dysfunction and mitochondrial impairment. This study investigates the relationship between DOX-induced cardiotoxicity and mitochondrial dysfunction in a rat model. Key cardiac function parameters and mitochondrial oxidative stress markers were assessed to determine the impact of DOX treatment. The results reveal significant deterioration in cardiac function and mitochondrial integrity, suggesting that mitochondrial damage is central to DOX-induced cardiotoxicity
No takes yet. Share an insight, caveat, or question.
Araa Mahdi Hussein AI-Rubaye (2026) studied Doxorubicin-induced cardiotoxicity. Doxorubicin was evaluated on Key cardiac function parameters and mitochondrial oxidative stress markers. Doxorubicin treatment caused significant deterioration in cardiac function and mitochondrial integrity in a rat model of cardiotoxicity.
Synapse has enriched 10 related papers. Consider them for comparative context: